Do erythropoietin and a blood transfusion guideline reduce the amount of packed red blood cells transfused in a major teaching hospital?

CHEST Journal ◽  
2004 ◽  
Vol 126 (4) ◽  
pp. 871S
Author(s):  
Nam T. Ly ◽  
Brian Cuneo ◽  
William L. Jackson ◽  
Nagla Wahab ◽  
Linda Gery ◽  
...  
PEDIATRICS ◽  
1981 ◽  
Vol 68 (6) ◽  
pp. 770-774 ◽  
Author(s):  
Linda M. Sacks ◽  
David B. Schaffer ◽  
Endla K. Anday ◽  
George J. Peckham ◽  
Maria Delivoria-Papadopoulos

The relative contribution of transfusions of adult blood to the development of retrolental fibroplasia (RLF) in very low-birth-weight infants was examined. Five years of experience with the expanded use of replacement and exchange transfusions in 90 infants with birth weight ≤1,250 gm was reviewed. Twenty percent of the infants developed cicatricial RLF. Exchange transfusion was not related to development of cicatricial RLF. The incidence of RLF in infants receiving ≥130 ml of packed red blood cells per kilogram of birth weight as replacement blood transfusion (RBT) was significantly higher (42.9%) than that in infants receiving 61 to 131 ml of packed red blood cells per kilogram (15.4%) and infants receiving ≤60 ml of packed red blood cells per kilogram (0%), P < .001. The need for RBT, however, was strongly correlated (r = .85, P < .001) with increasing duration of O2 therapy. When O2 therapy was controlled for, the association between RBT and RLF did not achieve statistical significance (P = .07). The association between RBT and RLF remained significant when adjusted for duration of therapy in fractional inspired oxygen (FIO2) >0.4. Further detailed studies of large numbers of susceptible infants are warranted to assess the magnitude of the contribution of transfusions of adult blood to development of RLF.


1992 ◽  
Vol 7 (4) ◽  
pp. 176-188 ◽  
Author(s):  
Thomas A. Mickler ◽  
David E. Longnecker

Blood transfusion is associated with immunosuppression, although the exact etiology of the immunosuppressive effect is not fully understood. The clinical significance of the immunosuppressive effect of blood transfusion has been examined in three situations: (1) studies of renal allograft survival after renal transplantation, (2) outcome studies in patients who have had surgical resection of solid cancer tumors, and (3) studies of infection rates in postoperative patients. In each scenario, the data support the conclusion that transfusion is associated with immunosuppression as manifested by increased renal allograft survival, increased recurrence and mortality rates in patients with cancer, and increased infection rates in postoperative patients who are transfused. Not all studies demonstrate an immunosuppressive effect of transfusion. There are several possible explanations for these discrepancies. First, prognostic variables other than transfusion itself account for the outcome results in these retrospective studies. Second, the extent of immunosuppression may be influenced by the type of blood product transfused, the amount transfused, and the timing of the transfusion; these factors have not been considered in all studies. For example, whole blood has been implicated as having a greater immunosuppressive effect than packed red blood cells, and many studies have shown that more than three units of packed red blood cells are necessary to affect outcome. Controlled animal studies have tested the hypothesis that transfusions increase solid tumor growth or the risk for infection. These studies have yielded conflicting results. Nevertheless, evidence that blood transfusion influences clinical outcome mitigates that a decision to transfuse must consider both risks and benefits of a transfusion; the possible consequences of immunosuppression must be included among the risks. Use of autologous blood, erythropoietin, and, in the future, synthetic hemoglobin may lead to improved outcome in patients with certain disease processes.


Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 966-966
Author(s):  
David Berz ◽  
Himani Singh ◽  
Elise McCormack ◽  
Eric Mazur

Abstract Background: Optimally the necessary laboratory evaluation for the diagnosis of the underlying causes for anemia is done before blood transfusion. However, clinical and logistical demands often mandate the transfusion of packed red blood cells before all the necessary parameters are obtained. It is poorly defined which impact transfusion has on the parameters necessary for the diagnosis of the underlying anemia cause. We conducted a prospective study to investigate the effect of the transfusion of two units packed red blood cells on lactate dehydrogenase(LDH), ferritin, transferrin, haptoglobin, total iron binding capacity(TIBC), folate, cyanocobalamine(B12), hemoglobin, MCV and hematocrit by measuring those tests before and at 6, 12, 24 and 48 hrs after transfusion. Patients and Methods: We included nineteen normovolemic, not actively bleeding consecutive patients; six of whom were diagnosed with anemia of chronic disease, one MDS and twelve iron deficiency anemias. Acutely bleeding patients, patients not able to give informed consent, prisoners under hospitalization and patients younger than 18 years old were excluded. All patients received transfusion of two units of packed red blood cells. The statistical analysis was performed using a repeated measurement ANOVA algorithm. Results: The transfusion of two units of packed red blood cells did not result in a significant change of ferritin, transferrin, haptoglobin, cyanocobalamin and lactate dehydrogenase throughout the observation period. Hemoglobin, MCV and hematocrit demonstrated an early change and equilibration without significant change after the first six hours post transfusion. Serum iron levels were transiently elevated in the severely iron deficient population, but returned back to baseline after 24hrs. Folate experienced a statistically significant, persistent change in the posttransfusion period. For the first 48 hrs post transfusion the following conclusions were made: First, the diagnosis of iron deficiency or chronic disease anemia is not confounded by blood transfusion, particularly when using ferritin as the predominant diagnostic parameter. Second, the diagnosis of hemolytic anemias, using haptoglobin and LDH is not interfered by transfusion of two units of packed red blood cells. Third, vitamin B12 deficiency can be diagnosed after transfusion, whilst folate deficiency on the base of red blood cell folate cannot.


2011 ◽  
Author(s):  
Arturo J Martí-Carvajal ◽  
Daniel Simancas ◽  
Ricardo Hidalgo

CJEM ◽  
2018 ◽  
Vol 21 (3) ◽  
pp. 365-373 ◽  
Author(s):  
Chase Krook ◽  
Domhnall O’Dochartaigh ◽  
Doug Martin ◽  
Zoë Piggott ◽  
Ryan Deedo ◽  
...  

ABSTRACTObjectivePrehospital blood transfusion has been adopted by many civilian helicopter emergency medical services agencies, and early outcomes are positive. The Shock Trauma Air Rescue Society operates six bases in Western Canada and started a blood on board process in 2013 in Regina that has expanded to all bases. Two units of O negative packed red blood cells are carried on every mission. We describe the processes and standard work ensuring safe storage, administration, and stewardship of this important resource.MethodsThe packed red blood cells are stored in an inexpensive, reusable temperature controlled cooler at 1°C–6°C. Close collaboration with local transfusion services and adherence to Canadian transfusion standards contributes to safety and sustainability.ResultsFrom October 1, 2013 to October 10, 2017, the Shock Trauma Air Rescue Society administered blood to 431 patients. Of this total, 62.9% received blood carried on our aircraft. A total of 463 blood box units were administered, and the majority of patients (69.0%) received both units. Blood used in Calgary, Alberta was 100% traceable, and only 1.2% of total units dispensed was wasted. The vast majority of unused units were returned to circulation.ConclusionWe describe the process to set up and monitor a prehospital blood transfusion program. Our standard work and stewardship processes minimize wastage of blood while keeping it readily available for our critically ill and injured patients.


2011 ◽  
Vol 115 (6) ◽  
pp. 1179-1191 ◽  
Author(s):  
Klaus Görlinger ◽  
Daniel Dirkmann ◽  
Alexander A. Hanke ◽  
Markus Kamler ◽  
Eva Kottenberg ◽  
...  

Introduction Blood transfusion is associated with increased morbidity and mortality. We developed and implemented an algorithm for coagulation management in cardiovascular surgery based on first-line administration of coagulation factor concentrates combined with point-of-care thromboelastometry/impedance aggregometry. Methods In a retrospective cohort study including 3,865 patients, we analyzed the incidence of intraoperative allogeneic blood transfusions (primary endpoints) before and after algorithm implementation. Results Following algorithm implementation, the incidence of any allogeneic blood transfusion (52.5 vs. 42.2%; P < 0.0001), packed red blood cells (49.7 vs. 40.4%; P < 0.0001), and fresh frozen plasma (19.4 vs. 1.1%; P < 0.0001) decreased, whereas platelet transfusion increased (10.1 vs. 13.0%; P = 0.0041). Yearly transfusion of packed red blood cells (3,276 vs. 2,959 units; P < 0.0001) and fresh frozen plasma (1986 vs. 102 units; P < 0.0001) decreased, as did the median number of packed red blood cells and fresh frozen plasma per patient. The incidence of fibrinogen concentrate (3.73 vs. 10.01%; P < 0.0001) and prothrombin complex concentrate administration (4.42 vs. 8.9%; P < 0.0001) increased, as did their amount administered per year (179 vs. 702 g; P = 0.0008 and 162 × 10³ U vs. 388 × 10³ U; P = 0.0184, respectively). Despite a switch from aprotinin to tranexamic acid, an increase in use of dual antiplatelet therapy (2.7 vs. 13.7%; P < 0.0001), patients' age, proportion of females, emergency cases, and more complex surgery, the incidence of massive transfusion [(≥10 units packed red blood cells), (2.5 vs. 1.26%; P = 0.0057)] and unplanned reexploration (4.19 vs. 2.24%; P = 0.0007) decreased. Composite thrombotic/thromboembolic events (3.19 vs. 1.77%; P = 0.0115) decreased, but in-hospital mortality did not change (5.24 vs. 5.22%; P = 0.98). Conclusions First-line administration of coagulation factor concentrates combined with point-of-care testing was associated with decreased incidence of blood transfusion and thrombotic/thromboembolic events.


Sign in / Sign up

Export Citation Format

Share Document